NCT05917938View on ClinicalTrials.gov

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

December 16, 2024

Study Completion Date

December 16, 2024

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

NNC0194-0499

NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.

Trial Locations (4)

81241

APEX Research, München

83101

Summit Clinical Research s.r.o., Bratislava

80-214

Uniwersyteckie Centrum Kliniczne (UCK), Gdansk

901 22

Summit Clinical Research s.r.o., Malacky

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY